Drug Trial Radar · NCT03069469
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Feb 16, 2017
Primary completion
Aug 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- Deciphera Pharmaceuticals, LLCIndustry
- Sponsor type
- Industry
- First posted
- Mar 3, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label Phase 1/2 study of vimseltinib in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2). Phase 1 will enroll both malignant solid tumor and TGCT patients. Phase 2 will comprise two cohorts (Cohort A and Cohort B) and will only enroll TGCT patients.
Conditions
- Advanced Malignant Neoplasm
- Pigmented Villonodular Synovitis
- Giant Cell Tumor of Tendon Sheath
- Tenosynovial Giant Cell Tumor
- Tenosynovial Giant Cell Tumor, Diffuse
Interventions
VimseltinibDrug
Colony-stimulating factor 1 receptor (CSF1R) inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD)Time frame: Day 1 - Day 28 of Cycle 1 for each dose level tested
- Number of Patients with Dose-Limiting Toxicities (DLTs)Time frame: Day 1- Day 28 of Cycle 1 for each dose level tested
- Time to maximum observed concentration of VimseltinibTime frame: Cycle 1 Day 1 and Day 8, and Cycle 2 Day 1 (pre-dose and at multiple time points (up to 8 hours) post-dose)
- Maximum observed concentration of VimseltinibTime frame: Cycle 1 Day 1 and Day 8, and Cycle 2 Day 1 (pre-dose and at multiple time points (up to 8 hours) post-dose)
- Trough observed concentration of VimseltinibTime frame: Cycle 1 Day 1 and Day 8, and Cycle 2 Day 1 (pre-dose and at multiple time points (up to 8 hours) post-dose)
- Area under the concentration-time curve (AUC) of VimseltinibTime frame: Cycle 1 Day 1 and Day 8, and Cycle 2 Day 1 (pre-dose and at multiple time points (up to 8 hours) post-dose)
- Half life of VimseltinibTime frame: Cycle 1 Day 1 and Day 8, and Cycle 2 Day 1 (pre-dose and at multiple time points (up to 8 hours) post-dose)
- Objective response rate (ORR= complete response [CR]+partial response [PR]) (Expansion Phase only)Time frame: At Week 25 (Cycle 7, Day 1)
- Duration of response rate (DOR) (Expansion Phase only)Time frame: Date from PR or CR to disease progression or death (Estimated up to 24 months)
Locations
24 sites in 9 countries. Site status is shown where the registry gives one.
Stanford Cancer Institute
Palo Alto, California
University of Colorado - Denver
Denver, Colorado
Mayo Clinic
Jacksonville, Florida
University of Miami
Miami, Florida
Dana Farber
Boston, Massachusetts
MSKCC
New York, New York
OHSU
Portland, Oregon
Oregon Health & Science University
Portland, Oregon
Sarah Cannon Research Institute
Nashville, Tennessee
Peter MacCallum Cancer Centre
Melbourne, Australia
Princess Margaret Cancer Center
Toronto, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Centre Leon Berard
Lyon, France
Gustave Roussy Cancer Campus Grand Paris
Paris, France
IRCCS Istituto Ortopedico Rizzoli
Bologna, Italy
Fondazione IRCCS Istituto Nazionale Dei Tumori
Milan, Italy
Istituto Nazionale dei Tumori
Milan, Italy
Regina Elena National Cancer Institute
Rome, Italy
Leiden University Medical Center
Leiden, Netherlands
M. Sklodowska-Curie Memorial Cancer Center
Warsaw, Poland
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital Clinico San Carlos
Madrid, Spain
Hospital Universitario Virgen del Rocío, Sevilla
Seville, Spain
University College Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.